|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 5,562,925: Scope, Claims, and Patent Landscape
Executive Summary
U.S. Patent No. 5,562,925, titled “Method for treating neurological diseases,” was granted on October 8, 1996, to Pharmacia & Upjohn Company. It broadly covers methods of treating neurological disorders, especially Parkinson's disease, using specific pharmaceutical compounds. This patent exemplifies significant patent protection in neuropharmacology, influencing subsequent patent filings, licensing, and clinical development. Its scope, claims, and position within the patent landscape reflect both its innovation and potential for patent litigation or exclusivity.
Introduction: Context and Significance
The patent pertains to methods for managing neurological disorders through the administration of particular pharmacological agents. As neurodegenerative diseases such as Parkinson's have limited treatment options, patents like this shape drug development by establishing exclusive rights over novel treatment methods.
Key details at a glance:
| Feature |
Detail |
| Patent Number |
5,562,925 |
| Issue Date |
October 8, 1996 |
| Assignee |
Pharmacia & Upjohn Company (now part of Pfizer) |
| Expiration |
October 8, 2013 (likely extended through patent term extensions) |
| Field |
Neuropharmacology / Neurological disease treatment |
| Core Focus |
Use of specific compounds for treating Parkinson's disease and related disorders |
What is the Scope of U.S. Patent 5,562,925?
Scope Overview
The patent claims delineate a method for treating neurological diseases characterized by dopaminergic deficits, primarily Parkinson's disease, by administering a specified class of compounds. The scope extends to:
- Method of treatment involving certain dopamine agonists.
- Application for preventing or alleviating symptoms associated with Parkinsonism and related disorders.
- Pharmacological composition comprising compounds with particular chemical structures.
Scope in Claim Language
Primary Claims (Claims 1–6):
- Focus on “a method for treating a neurological disorder characterized by dopaminergic deficiency,” involving administration of at least one compound with a specified chemical structure.
- Claim 1, considered the independent claim, specifies:
"A method of treating Parkinson's disease comprising administering to a patient in need thereof an effective amount of a compound of formula I..."
- Formula I encompasses dopaminergic agonists with particular substituents, such as non-ergoline derivatives, including bromocriptine analogs.
Dependent Claims:
- Narrower claims specify particular compounds, dosages, or treatment regimens.
- Cover combinations with other agents (e.g., L-DOPA).
Chemical Scope
The patent's chemical scope covers a family of compounds, including:
| Compound Class |
Examples |
Structural Features |
| Non-ergoline dopamine agonists |
Pergolide, bromocriptine analogs |
Substituted phenylpiperazines, etc. |
| Specific substituents |
Chlorine, bromine, methyl groups |
Variations influence potency and selectivity |
Claims Analysis: What Is Legally Covered?
| Claim Type |
Content |
Implication |
| Independent Claims |
Broad method claims covering a class of compounds and indications |
Establishes the core patent monopoly |
| Dependent Claims |
Narrower claims on particular compounds, dosages, and combinations |
Provide fallback positions in infringement disputes |
Key Claims Breakdown
| Claim No. |
Title |
Scope |
Unique Aspects |
Limitations |
| 1 |
Treatment Method |
Admin of compounds of formula I |
Focused on Parkinson's diseases |
Requires specific chemical structures |
| 2-6 |
Refinements |
Specific compounds, dosages, or formulations |
Narrower, more specific |
Limited to particular embodiments |
Patent Landscape for Neurological Disease Treatments
Pre- and Post-Patent Filing Landscape
| Period |
Key Patents & Developments |
Industry Focus |
| Pre-1990 |
Early dopamine agonist formulations (e.g., bromocriptine) |
Basic pharmacotherapy for Parkinson’s |
| 1990–2000 |
Expansion into non-ergoline agents, target-specific compounds |
Innovative compounds like those in ‘925 patent |
| Post-2000 |
Emergence of selective dopamine receptor agonists (e.g., pramipexole, ropinirole) |
Increased patent filings for specificity and effectiveness |
Major Patent Families & Competitors
| Patent Family |
Focus |
Assignees |
Status |
Year of Publication or Expiry |
| Pfizer/Pharmacia |
Method of treating Parkinson's with compounds of formula I |
Pfizer |
Active (prior to expiration) |
1996–2013 (patent expiry) |
| Eli Lilly |
Dopamine receptor agonists |
Eli Lilly |
Active or expired |
1990s–2000s |
| Other filings |
Non-ergoline receptor agonists, new chemical entities |
Multiple biotech firms |
Ongoing |
2000s–present |
Legal and Market Impact
- The patent provided exclusivity for specific treatment methods for approximately 17 years.
- It served as a basis for licensing agreements, generics challenges, and subsequent patent filings.
- Its expiration opened the market for generic versions and further innovation.
Comparison of Patent Claims: U.S. Patent 5,562,925 and Similar Patents
| Patent Number |
Focus |
Structural Scope |
Activity Area |
Key Differentiator |
| 5,562,925 |
Dopamine receptor agonists for Parkinson’s |
Formula I compounds |
Parkinson's disease treatment |
Specific chemical structures and methods |
| 6,174,558 |
Novel dopamine agonists with improved selectivity |
Novel structures |
Dopaminergic disorders |
Enhanced receptor affinity |
| 7,123,456 |
Combination therapies |
Multiple agents |
Parkinson's and other neuro disorders |
Multi-drug approaches |
Implications for Innovators and Practitioners
- Patent scope limits: While broad, the claims do not cover all dopamine agonists or all neurological conditions, allowing room for competitors with different chemical classes.
- Design-around opportunities: Alternative compounds outside the claimed chemical structures can bypass the patent.
- Patent expiry: As patent 5,562,925 has expired, generic manufacturers can now produce treatments under applicable patent laws.
Conclusion: Strategic Takeaways
- Patent Scope: The patent’s claims protect specific chemical structures used in treating Parkinson's disease, with a method-of-use focus.
- Legal Landscape: It intersects with a compound family of neuroactive agents, influencing subsequent patent filings.
- Market Impact: This patent facilitated patent exclusivity during its term, shaping the neuropharmacology market.
- Innovation Pathways: Modern development has shifted toward receptor selectivity and novel mechanisms, yet existing patents like 5,562,925 laid foundational groundwork.
Key Takeaways
- U.S. Patent 5,562,925 covers a class of dopamine agonist compounds and their use in treating Parkinson's disease.
- Its claims focus on chemical structures specified in formula I, with method claims that provide broad coverage for therapeutic administration.
- The patent landscape is characterized by significant filings for alternative agents and combination therapies, with this patent serving as a milestone in neuropharmacological innovation.
- Expiration of the patent in 2013 led to increased market competition and generic production.
- Navigating patent claims requires assessing chemical scope, potential design-arounds, and evolving therapy approaches to maintain competitive advantage.
FAQs
1. Does U.S. Patent 5,562,925 cover all dopamine agonists used in Parkinson’s disease?
No. It covers specific compounds defined by formula I. Other dopamine agonists outside this structure, like pramipexole or ropinirole, are not explicitly covered unless they fall within the claimed chemical scope.
2. Are methods of treatment patentable in the United States?
Yes. Patent claims can encompass methods of administering or using compounds for therapeutic purposes, as exemplified by patent 5,562,925.
3. What are the implications of the patent expiry for generic producers?
Post-expiry, generic companies can manufacture and sell medications based on the compounds or methods described, subject to other patent or exclusivity protections.
4. How does this patent influence current drug development strategies?
It established a foundation for neuropharmacological claims, prompting newer compounds targeting receptor selectivity, pharmacokinetic improvements, and combination therapies to innovate beyond this scope.
5. Are there ongoing patent litigations related to this patent?
While specific litigations are not well-documented post-2013, similar patents and subsequent formulations have faced litigation, emphasizing the importance of patent strategy in neuropharmacology.
References
[1] United States Patent and Trademark Office. “Patent Number: 5,562,925,” issued October 8, 1996.
[2] Keck, Peter C., et al. “The neuropharmacology of dopamine receptor agonists,” Neuroscience, 1998.
[3] WIPO Patent Landscape Reports. “Dopamine Agonists for Parkinson’s Disease,” 2005.
[4] FDA Drug Approvals and Patent Data, 1990–2013.
[5] PatentScope, WIPO, “Major neuropharmacology patent families.”
More… ↓
⤷ Start Trial
|
